Evidence map›Paper›PMID 28539323›Full record

ArticleCancer research2017

ETV1-Positive Cells Give Rise to

Leili Ran, Devan Murphy, Jessica Sher, Zhen Cao, Shangqian Wang, Edward Walczak, Youxin Guan, Yuanyuan Xie, Shipra Shukla, Yu Zhan and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Treatment ofJournal of gastrointestinal oncology · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Leili RanHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Devan MurphySchool of Veterinary Medicine, University of California, Davis, California.
Jessica SherHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Zhen CaoHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Shangqian WangHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Edward WalczakHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Youxin GuanHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Yuanyuan XieHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Shipra ShuklaHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Yu ZhanHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.
Cristina R AntonescuDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York. chip@mskcc.org cheny1@mskcc.org.
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York. chip@mskcc.org cheny1@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SPRIGGS, DAVID R · 2010 to 2014
$11.1M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
An integrative approach to target lineage-specific oncogenic transcription factorDP2CA174499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2012 to 2012
$2.6M
Elucidating the roles of ETV1 in the pathogenesis of GISTK08CA151660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2011 to 2015
$848k
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.K08CA140946 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2009 to 2013
$796k
NCI NIH HHS DP2 CA174499NCI NIH HHS K08 CA140946NCI NIH HHS K08 CA151660NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA140146NCI NIH HHS R01 CA193837
6 · The paper itself

Abstract

Gastrointestinal stromal tumor (GIST) is the most common subtype of sarcoma. Despite clinical advances in the treatment of

Indexed as

AnimalsDisease Models, AnimalDNA-Binding ProteinsGastrointestinal NeoplasmsGastrointestinal Stromal TumorsMiceMice, SCIDMutationProto-Oncogene Proteins B-rafTranscription FactorsBraf protein, mouseDNA-Binding ProteinsEtv1 protein, mouseProto-Oncogene Proteins B-rafTranscription Factors

Identifiers

PMID28539323
PMCPMC5513719
OpenAlexW2617878926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.